We are currently conducting three international clinical research studies; two Phase 3 studies with linzagolix in women with heavy menstrual bleeding associated with uterine fibroids (PRIMROSE 1 & 2), and one Phase 3 study with linzagolix in women with endometriosis-associated pain (EDELWEISS 3).